Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapy: a retrospective study

Fig. 2

Tree-structured survival model. More than one metastatic lymph node was a primary determining prognostic factor (p = 0.004). UGT1A1 polymorphism was a secondary determining high-risk factor for recurrence (p = 0.024). PFS: progression-free survival; meta: metastasis; UTG1A1: uridine diphosphate glucuronosyltransferase 1A1; p < 0.05*

Back to article page